Dendreon seeks Chapter 11 bankruptcy as $620m debt looms

Dendreon said late on 9 November that it has reached an agreement with certain holders of its convertible senior notes due in 2016 to seek Chapter 11 bankruptcy so that it can reorganize, sell the company or dispose of its assets to manage $620m in debt that must be repaid in 14 months.

More from Anticancer

More from Therapy Areas